Windlas Biotech Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/x374gla6pa26eb11ljjgj8qd.pdf

Key Takeaways


Revenue Growth & Business Mix

Hitesh Windlass: "We are actually very proud to say this, Sir that we have never lost a customer in the last 20 years, 20-plus years. We might have said no to a customer, but we have never really lost a customer."

Injectable Facility: Timeline, Scope & Economics

Hitesh Windlass: "We have also added one more section, which is lyophilized vials, which is high in high demand in export markets. So, there is a cost increase compared to our initial estimate."

Margin Dynamics & Investment Posture

Komal Gupta: "There can be a 2% to 3% growth in the current EBITDA margin."

Trade Generics: The Blue-Ocean Bet

Hitesh Windlass: "This is almost a Blue ocean kind of a space. And we really believe that a huge way to grow is possible over here."

Regulatory & Competitive Positioning

Hitesh Windlass: "See, actually, we believe this is a great opportunity for responsible and established players like Windlas. All our facilities are already complying to WHO GMP guidelines, which the regulator is now pushing and asking other industries also to step up to."

Capital Allocation & Shareholder Returns


Guidance & Commitments

CommitmentSpecificsTimeline
Injectable facility mechanical completionMechanical completion by end of Q2 FY24 (September)End of Q2 FY24
Injectable facility commercializationCommercialization expected, revenues thereafterQ4 FY24
EBITDA margin expansion2% to 3% growth in current EBITDA marginMedium term (3-4 years)
Dividend payout20% of consolidated profitsOngoing (as done in FY22)
R&D spend~1.5%-2% of sales annuallyOngoing
Capacity expansion triggerNew facility needed if average monthly revenue reaches ~₹50 croresWhen trigger met
Capex for next five years' capacity~₹40 crores spent phase-wise, plus ₹10-₹15 crores annual de-bottleneckingNext five years
Export revenue materializationMost results of current filings show up in year three, year four and onwards3-4+ years from filing

Key Metrics

MetricQ1 FY24
Revenue₹145 cr, +21% YoY
CDMO revenue₹110.2 cr, +14% YoY, 76% of consolidated revenue
Trade Generics & Institutional revenue₹30.8 cr, +44% YoY, 21% of consolidated revenue
Exports revenue₹3.8 cr, +94% YoY, 3% of consolidated revenue
EBITDA₹17 cr, +24% YoY
EBITDA margin11% to 12% range over last 8-9 quarters
Profit after tax₹12 cr, +23% YoY
EPS₹5.79, +29% YoY from ₹4.50 in Q1 FY23
Capacity utilization~50%; peak CDMO utilization globally is 60-65%
Revenue capacity from current facilities~₹600 cr; can be enhanced by 10-15% with small capex
R&D spend~₹2 cr in Q1; ~1.5% to 2% of sales annual run-rate
Liquidity position₹138 cr as on March 31, 2023
Buyback completed₹25 cr in Q1 FY24
Injectable facility capex~₹70 cr, up from ~₹50 cr estimated two years ago; mechanical completion expected by end of Q2 FY24
Facility audits per year~70 times across all facilities